Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/51149
Title: Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
Authors: Kahraman, Seda
Erul, Enes
Seyyar, Mustafa
Gümüşay, Özge
Bayram, Ertuğrul
Çakan Demirel, Burçin
Acar, Ömer
Aksoy, Sercan
Baytemur, Naziyet Kose
Sahin, Elif
Cabuk, Devrim
Basaran, Gül
Paydas, Semra
Yaren, Arzu
Guven, Deniz Can
Erdogan, Atike Pinar
Demirci, Umut
Yasar, Alper
Bayoglu, Ibrahim Vedat
Hizal, Mutlu
Gulbagci, Burcu
Paksoy, Nail
Yilmaz, Funda
Dogan, Ozlem
Orhan, Sibel Oyucu
Kayikcioglu, Erkan
Aytac, Ali
Keskinkilic, Merve
Mocan, Eda Eylemer
Unal, Olcun Umit
Aydin, Esra
Yucel, Hakan
Isik, Deniz
Eren, Onder
Uluc, Basak Oyan
Ozcelik, Melike
Hacibekiroglu, Ilhan
Aydiner, Adnan
Demir, Hacer
Oksuzoglu, Berna
Cilbir, Ebru
Cubukcu, Erdem
Cetin, Bulent
Oktay, Esin
Erol, Cihan
Okutur, Sadi Kerem
Yildirim, Nilgun
Alkan, Ali
Selcukbiricik, Fatih
Aksoy, Asude
Karakas, Yusuf
Ozkanli, Gulhan
Duman, Berna Bozkurt
Aydin, Dincer
Dulgar, Ozgecan
Er, Muhammed Muhiddin
Teker, Fatih
Yavuzsen, Tugba
Aykan, Musa Baris
Inal, Ali
Iriagac, Yakup
Kalkan, Nurhan Onal
Keser, Murat
Sakalar, Teoman
Kut, Engin
Bilgin, Burak
Karaoglanoglu, Muge
Sunar, Veli
Ozdemir, Ozlem
Turhal, Nazim Serdar
Karadurmus, Nuri
Yalcin, Bulent
Sendur, Mehmet Ali Nahit
Keywords: CDK 4
6 inhibitors
HER2-negative metastatic breast cancer
HR-positive
letrozole
Publisher: Future Medicine Ltd
Abstract: Background: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Methods: The authors report retrospective real-life data for 600 patients with estrogen receptor- and/or progesterone receptor-positive and HER2-negative metastatic breast cancer who were treated with ribociclib and palbociclib in combination with letrozole. Results & conclusion: The results demonstrated that the combination of palbociclib or ribociclib with letrozole has similar progression-free survival and overall survival benefit in real life for the patient group with similar clinical features. Specifically, endocrine sensitivity may be a factor to be considered in the treatment preference.
Description: Article; Early Access
URI: https://doi.org/10.2217/fon-2022-1287
https://hdl.handle.net/11499/51149
ISSN: 1479-6694
1744-8301
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Show full item record



CORE Recommender

SCOPUSTM   
Citations

5
checked on Oct 13, 2024

WEB OF SCIENCETM
Citations

4
checked on Oct 22, 2024

Page view(s)

66
checked on Aug 24, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.